Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
One Percent Rule Checklist For Safer Forex Trading Risk 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
AstraZeneca's suspension of global trials of its coronavirus vaccine dubbed AZD1222 triggered a 2 percent drop in its shares in London and a 12 plunge in the stock price of its Indian unit, AstraZeneca Pharma India Ltd.
The company is developing the AZD1222 vaccine with the University of Oxford.
The suspension, which dimmed the company's prospect of an early rollout, was necessary to review safety data after an unexplained illness in a participant.
AstraZeneca said that the suspension was routine every time there is a potentially unexplained illness in the trials.
The company is working to expedite the review to minimize any potential impact on the trial timeline.
The decision on restarting the trial will be taken by the medical regulator, the MHRA, that would take only days.
According to a New York Times report, citing a person familiar with the situation, the UK-based participant was found to have transverse myelitis, an inflammation that affects the spinal cord and is often sparked by viral infections.
Whether the condition was directly linked to AZD1222 remains unclear.
The AZD1222 has been described by the World Health Organization (WHO) as probably the world’s leading and the most advanced vaccine.
The vaccine is in late-stage clinical trials in the US, the UK, Brazil, and South Africa.
Additional trials are planned in Russia and Japan, targetting up to 50,000 participants globally.
The participant's reaction to AZD1222 has impacted clinical trials by other vaccine makers, which are on the lookout for similar reactions.
